Life Synergy · Looking Closer
Psilocybin and the Science of Healing
I put this research together because curiosity deserves more than a beautiful promise. Here is what I find encouraging about psilocybin, what remains uncertain, and why the care around an experience matters to me.
By Juan Rendon, founder and lead facilitator, Life Synergy RetreatUpdated · 35-minute read · 42 sources
- 42studies and sources, every one linked
- 2positive phase 3 trials, in 2025 and 2026
- 2–4×remission rates versus the comparison group in three randomized trials
- 4.5 yrslongest follow-up, with 60–80% still responding
The short version
What the science says about psilocybin
- Psilocybin quiets the brain’s default mode network, its autopilot for rumination, and opens a short window in which the brain is unusually adaptable.
- In three randomized depression trials, remission rates after psilocybin were two to four times those of the comparison groups (not every gap was statistically significant), and two phase 3 trials confirmed a more modest but significant benefit in 2025 and 2026.
- After one or two sessions, benefits often lasted months and sometimes years, and the depth of the mystical experience predicted how long.
- Trials in alcohol and tobacco dependence and in distress with serious illness are promising; the evidence for trauma and for slowing aging is still early.
- Meditation and breathwork reach similar brain states by slower or shorter roads. Combining them with psilocybin is reasoned practice, not yet proven practice.
- The risks are mostly psychological and situational. Screening, honesty about medications (lithium above all) and skilled, present guides matter most.
Educational, not medical advice. Psilocybin is not an approved medicine and remains a controlled substance in most countries. Life Synergy offers a guided wellness experience, not medical treatment.
A letter from Juan
A personal note before the science
If you're reading this, you may be curious, hopeful, a little nervous, or some combination of all three. I wanted to make a place where those feelings could sit beside the research without either one having to leave the room. There is enough excitement around psilocybin already. What I wanted was a slower, more useful conversation.
I've been hosting retreats in Playa del Carmen since 2013. That experience gives me a reason to care deeply about these questions, but it doesn't make me a doctor or a scientist. I'm the founder and lead facilitator of Life Synergy. My responsibility here is to be clear about what the studies say, what they don't say, and where my own perspective begins.
Some of what follows is genuinely encouraging. Some is preliminary. A few headlines could probably use a quiet afternoon away from the internet. I've kept the sources close so you can look beyond my enthusiasm and form your own understanding. You don't have to share my beliefs to ask good questions.
My hope is that you finish this page feeling better informed, not talked into anything. Perhaps it opens a conversation with your clinician, with someone you trust, or with us. Perhaps it helps you decide to wait. There is room for that too.
Chapter 1
Why psilocybin has the attention of modern psychiatry
I want to understand why the research matters without letting enthusiasm get ahead of it.
In 2006, researchers at Johns Hopkins gave psilocybin to 36 healthy volunteers who had never taken a psychedelic. Two months later, 67% ranked the session among the five most meaningful experiences of their lives, in the same category as the birth of a child or the death of a parent [1]. Fourteen months on, most still did, and reported lasting gains in well-being [2].
That one study reopened a field that had been frozen for three decades. Since then psilocybin, the active compound in more than 200 species of mushrooms used ceremonially in Mesoamerica for thousands of years, has been tested in randomized trials for depression, end-of-life anxiety, alcohol and tobacco dependence, and more. The U.S. Food and Drug Administration granted it “Breakthrough Therapy” status in 2018 and 2019, and the first phase 3 trials, the last step before approval, reported results in 2025 [14].
This page walks through what the research shows, where it is still thin, and how psilocybin relates to practices such as breathwork and meditation. It is written in plain language, with every source linked so you can read the studies yourself.
Timeline
From ceremony to clinical trials
- Centuries
Mushrooms containing psilocybin are used in ceremony across Mesoamerica.
- 1970s to 2000s
Research is largely frozen for three decades.
- 2006
Johns Hopkins: 67% of 36 volunteers rank their session among the five most meaningful experiences of their lives [1].
- 2012
Imperial College brain scans show the default mode network quieting under psilocybin [3].
- 2016
Cancer trials: about 80% of patients show large drops in depression and anxiety, lasting at least six months [16].
- 2018–2019
The FDA grants psilocybin “Breakthrough Therapy” status.
- 2021
Head to head with escitalopram, remission is 57% versus 28% [10].
- 2024
A BMJ meta-analysis pools seven randomized trials [15]; Nature publishes the brain-synchrony study [7].
- 2025
The first phase 3 trial reports a significant benefit [14]; the first aging study, in cells and mice [24].
- 2026
A second phase 3 trial confirms it, and the FDA agrees to a rolling review of the application [14].
Chapter 2
What psilocybin is, and what it does in the brain
I'm interested in what the brain reveals, and in what we choose to do after an experience.
Psilocybin is a “prodrug”: the body converts it into psilocin, a molecule shaped so much like serotonin that it docks onto the serotonin 2A receptor (5-HT2A). Those receptors are densest in the cortex, the brain’s outer layer responsible for perception, thinking and the sense of self. The acute effects last four to six hours, and it does not produce the compulsive use seen with alcohol, nicotine or opioids.
Three findings matter most.
The brain’s “autopilot” quiets down
The default mode network (DMN) switches on when we are not focused on the outside world: daydreaming, replaying the past, rehearsing the future, narrating our own story. In 2012, Imperial College London scanned volunteers during psilocybin and found blood flow and connectivity in the DMN’s hubs fell, and the more they fell, the stronger the experience [3]. Depression and anxiety involve an overactive, rigid DMN (rumination, clinically), so a drug that loosens it is of obvious interest. Notably, experienced meditators show the same pattern of reduced DMN activity during practice [4].
The brain’s networks desynchronize, then re-form
In 2024, Washington University scanned seven adults repeatedly before, during and after psilocybin. It changed the brain’s functional connectivity more than three times as much as a high dose of methylphenidate (Ritalin); most of that faded quickly, but weaker connectivity between the hippocampus and the DMN was still measurable weeks later [7]. The disruption shrank when participants did a simple perceptual task, a hint at why grounding and guidance matter during a session.
Neurons grow new connections
In cultured neurons, psychedelics increased the branching of dendrites, the tree-like structures that receive signals from other cells [5]. In living mice, a single dose of psilocybin increased the density and size of dendritic spines (the tiny docking points on those branches) in the frontal cortex by about 10% within 24 hours, and the new spines were still there a month later [6]. Scientists call this window of heightened adaptability neuroplasticity: the brain briefly becomes more moldable, which is why what you do in the days and weeks after a session (integration, therapy, meditation) appears to matter as much as the session itself.
How it works
From mushroom to lasting change, in six steps
- 1
Converted
The body turns psilocybin into psilocin, a close chemical cousin of serotonin.
- 2
Docks
Psilocin binds the serotonin 2A receptor, densest in the cortex.
- 3
Quiets
Activity in the default mode network, the brain’s autopilot, falls [3].
- 4
Loosens
Usual network patterns desynchronize, then re-form; some changes last weeks [7].
- 5
Grows
New dendritic spines appear within 24 hours in mice and are still there a month later [6].
- 6
Integrates
What you practice in the following days and weeks helps shape what lasts.
Steps 1 to 4 are measured in people, step 5 in animals; step 6 is the reasoning behind integration.
Integration is the part people underestimate. Our guide, Integration After a Psychedelic Experience, covers the practical side.
Chapter 3
What the clinical trials show for mental health
I welcome encouraging findings without confusing a clinical trial with a retreat.
Depression. In a Johns Hopkins trial, 24 adults with major depression received two psilocybin sessions with psychological support. Four weeks later, 71% had responded (symptoms at least halved) and 54% were in remission [8]. A year later, with no further doses, 58% remained in remission [9]. Imperial College then ran a six-week trial against the antidepressant escitalopram. The difference on the main depression scale was not statistically significant, but remission was 57% with psilocybin versus 28% with escitalopram [10], and six months on the psilocybin group was doing better on day-to-day functioning, connectedness and sense of meaning [11].
Larger, industry-run trials have been more sober but still positive. In a 233-person study of treatment-resistant depression, a single 25 mg dose beat a 1 mg comparison dose at three weeks, with 29% versus 8% in remission [12]. A 104-person trial against a niacin placebo found a 12-point larger drop on the clinician-rated depression scale, and 42% versus 11% kept their response through six weeks [13]. Two phase 3 trials of 258 and 581 people met their main goal at six weeks in 2025 and 2026, with a more modest benefit than the earlier, smaller trials (3.6 and 3.8 points on that scale over the 1 mg comparison dose); the developer began a rolling FDA submission in 2026 and aims to complete it by the end of the year [14]. Pooling the randomized trials, a 2024 BMJ meta-analysis found a medium-to-large effect (Hedges g 0.66) and remission about three times as likely as in control groups [15].
Chart 1 · Depression
In three randomized trials, remission after psilocybin ran two to four times the comparison group
Share in remission at each trial’s main time point. Remission was a secondary outcome in all three, and the Usona difference was not statistically significant.
Imperial College, 2021vs escitalopram · 6 weeks
COMPASS phase 2b, 2022vs 1 mg control dose · 3 weeks
Usona phase 2, 2023vs niacin placebo · 6 weeks, sustained
Data: Carhart-Harris et al. 2021, NEJM; Goodwin et al. 2022, NEJM; Raison et al. 2023, JAMA (sustained remission, days 8–43). Chart: Life Synergy.
The comparators differ, and not every gap was statistically significant, but the direction is consistent.
Anxiety and existential distress. The first headline trials were in people with life-threatening cancer. At Johns Hopkins, a single high dose produced clinically significant reductions in depression and anxiety in about 80% of patients, still present six months later [16]. At NYU, a follow-up tracked patients for an average of 4.5 years: 60 to 80% still met criteria for a clinically significant response, and 71 to 100% attributed positive life changes to the experience [17].
Addiction. In a 93-person trial for alcohol use disorder, two psilocybin sessions alongside psychotherapy cut heavy-drinking days by 83% over eight months, versus 51% with an active placebo and the same psychotherapy, and 48% versus 24% were fully abstinent in the final four weeks [18]. In a smoking pilot, 80% of long-term smokers were confirmed abstinent at six months, 67% at a year and 60% about two and a half years later [19]. A 2026 pilot randomized trial of 82 smokers then pitted a single dose against 8 to 10 weeks of nicotine patches, both with the same counseling program: 41% versus 10% were confirmed abstinent at six months [20].
Chart 2 · Addiction
In the addiction trials, two to four times as many people quit
Share of participants abstinent at follow-up, psilocybin versus the comparison group
Alcohol use disorder abstinent in the final 4 weeks of an 8-month trial [18]
Data: Bogenschutz et al. 2022, JAMA Psychiatry; Johnson et al. 2026, JAMA Network Open. Chart: Life Synergy.
Trauma. The evidence here is newest and thinnest. No randomized trial of psilocybin for post-traumatic stress disorder has published results yet; one at Johns Hopkins finished collecting its main data in 2026. In an open-label study of 22 people, with no control group, 82% responded and 64% were in remission on the clinician PTSD scale four weeks after a single dose [21]; in a 2026 pilot, 9 of 12 veterans with severe, treatment-resistant PTSD were in remission a month after two doses [22]. Open-label studies overestimate effects, so treat these as promising signals rather than proof; MDMA has the stronger PTSD evidence (see the comparison below).
Chart 3 · Durability
Months to years after one or two sessions, 58–80% of participants still showed the benefit
Share of participants with the outcome at follow-up; darker bars are longer follow-ups
- Smoking: confirmed abstinent, Hopkins pilot80% at 6 months
- Cancer distress improved, Hopkins trial80% at 6 months
- Smoking: confirmed abstinent, Hopkins pilot67% at 12 months
- Depression in remission, Hopkins trial58% at 12 months
- Session in top 5 most meaningful, Hopkins58% at 14 months
- Smoking: confirmed abstinent, Hopkins pilot60% at 2.5 years
- Cancer distress improved, NYU trial60–80% at 4.5 years
Data: Johnson et al. 2017; Griffiths et al. 2016; Gukasyan et al. 2022; Griffiths et al. 2008; Agin-Liebes et al. 2020 (the 60–80% range shown as a striped band). Chart: Life Synergy.
These are the same trials cited above, followed over time.
The evidence map
How strong is the evidence, use by use?
I don't give every finding the same weight. This is my reading of evidence strength, from cells and mice to phase 3 trials, not a score for what a retreat can do for you. The gaps matter as much as the encouraging results.
- DepressionPhase 3 trialsTwo positive phase 3 trials and a meta-analysis of seven randomized trials
- Distress with serious illnessRandomized trialsRandomized trials at Johns Hopkins and NYU
- Alcohol useRandomized trialsOne randomized trial of 93 people
- SmokingRandomized trialsA pilot study and a small randomized trial against the nicotine patch
- PTSDOpen-label studiesOpen-label studies only; no randomized trial results yet
- Pairing with meditationRandomized trialsTwo randomized studies
- Pairing with breathworkNot yet testedNo controlled trial yet
- Slowing agingCells and animalsCells and mice only
- Cells and animals
- Case reports and surveys
- Open-label studies
- Randomized trials
- Phase 3 trials
Life Synergy’s reading of the studies on this page, October 2026; not a medical rating.
Chapter 4
The mystical experience, and why it predicts lasting change
I make room for spiritual meaning without asking anyone to have a particular kind of experience.
Researchers measure the peak of a psilocybin session with the Mystical Experience Questionnaire (MEQ30). It asks about six things:
- 1
Unity
A sense of unity with everything
- 2
Time and space
The feeling that time and space dissolved
- 3
Positive mood
A deeply felt positive mood
- 4
Sacredness
A sense of sacredness
- 5
Noetic quality
A conviction of having touched something true
- 6
Ineffability
The impossibility of putting it into words
Score highly on all of them and researchers call it a “complete” mystical experience. In the 2006 Hopkins study, 61% of volunteers had one [1].
In the Imperial College trial for treatment-resistant depression, two features of the session, the depth of the mystical “oceanic” state and how little dread people felt as their sense of self loosened, together predicted 54% of the change in depression scores five weeks later, in an exploratory analysis of 19 people [23]. In the Hopkins cancer trial, mystical-experience scores statistically accounted for the improvements in mood [16]. The experience itself appears to be part of the medicine, which is why clinical protocols invest so heavily in preparation, music, eyeshades and a trusted guide.
- 61%had a “complete” mystical experience in the 2006 Hopkins study [1]
- 54%of the change in depression five weeks later was predicted by two features of the session, in a small exploratory analysis [23]
- 67%still ranked it among their five most spiritually significant experiences 14 months later [2]
For spiritual health the data are consistent. At 14 months, 58% of the original Hopkins volunteers still rated the session among the five most meaningful experiences of their lives, 67% among the five most spiritually significant, and 64% said it had increased their well-being [2]. Participants typically describe greater connectedness to other people and to nature, more gratitude, and a softer relationship with death, whether or not they consider themselves religious. As the brain section suggests, the temporary dissolving of the boundary between “me” and “everything else” (ego dissolution) tracks closely with the quieting of the default mode network [3].
I want you to feel better informed, not talked into anything.
Chapter 5
Anti-aging and longevity: a promising, very early frontier
I'm curious about this frontier, but curiosity isn't evidence that people will live longer.
In 2025, researchers at Emory University and Baylor College of Medicine published the first study of psilocybin and aging, in the Nature journal npj Aging [24]. In human lung cells, psilocin extended replicative lifespan by 29% at a low dose and 57% at a high dose, and adult skin cells lived 51% longer; treated cells showed less oxidative stress, better-preserved telomeres (the protective caps on chromosomes that shorten with age) and more SIRT1, a protein linked to longevity. They then gave 19-month-old female mice, roughly 60 to 65 in human years, psilocybin once a month for ten months: 80% of treated mice were alive at the end versus 50% of untreated mice.
Preclinical: cells and mice, not people
Two honest caveats
These are cells and mice, not people, and nobody has tested whether it translates to human lifespan; and monthly dosing for ten months bears no relation to how people use psilocybin. What the finding does do is join a wider picture in which psilocybin’s effects reach beyond mood: activating the same 5-HT2A receptor has strong anti-inflammatory effects in animal studies [25], and chronic low-grade inflammation is one of the main engines of biological aging. Healthy skepticism is warranted; so is interest.
Chapter 6
Psilocybin, meditation and breathwork: three roads to a similar place
I value the practices that can come home with you, not only the experience that brings you here.
Put the brain findings side by side and a pattern appears. Long-term meditators show reduced default-mode-network activity during practice, across several styles of meditation [4]. Psilocybin produces the same quieting pharmacologically, within an hour, in people who have never meditated [3]. And fast, deep breathwork roughly halves the carbon dioxide in exhaled breath, which can produce altered states: in a 2025 study of 61 experienced practitioners of holotropic or conscious connected breathing, the active breathers scored on all four MEQ30 mystical-experience subscales much like published groups given a moderate dose of psilocybin (a comparison with earlier studies, not a head-to-head test), and a subgroup reported a large drop in depressive symptoms a week later [26]. Three routes, one destination: less rumination, more flexibility, a softer sense of self.
| Practice | Evidence for depression and anxiety | Time to effect | How long it lasts | Main risks |
|---|---|---|---|---|
| Psilocybin | Medium-to-large effect, 7 randomized trials [15] | Hours; one session | Weeks to months, sometimes years | Challenging experiences; drug interactions; unsuitable for psychosis-prone people |
| Meditation | Small-to-moderate, 47 trials [27] | Weeks to months of daily practice | Grows with practice; fades without it | Minimal; rare destabilization in intensive retreats |
| Breathwork | Small-to-moderate, 12–20 trials [28] | Minutes; one session | Hours to days; grows with practice | Dizziness, tingling, fainting; caution in pregnancy and heart conditions |
Chart 4 · Effect sizes
Psilocybin lands in the medium-to-large range; meditation and breathwork in the small-to-moderate range
Effect size (Hedges g) against each study’s own control group; dashed lines mark the usual small, medium and large thresholds
- Psilocybin: depression0.66
- Breathwork: depression0.40
- Meditation: anxiety0.38
- Breathwork: stress0.35
- Breathwork: anxiety0.32
- Meditation: depression0.30
Data: Metaxa & Clarke 2024, BMJ (corrected estimate); Goyal et al. 2014, JAMA Internal Medicine (8-week effects); Fincham et al. 2023, Scientific Reports. Chart: Life Synergy.
Each bar is measured against that practice’s own control group, so read them as size of change, not as a ranking.
Do they work better together? Two studies suggest so. In Zurich, 39 experienced meditators on a five-day mindfulness retreat were randomized to psilocybin or placebo on day four. Nineteen of the 20 given psilocybin had a strong mystical-type experience, against 3 of 19 on placebo, with almost no anxiety, and four months later they reported positive changes in their lives about four times larger than the placebo group did [29]. At Johns Hopkins, 75 adults without a regular meditation practice received psilocybin with either light or intensive support for a daily meditation practice; at six months, 96% of the high-dose, high-support group rated the experience among the five most spiritually significant of their lives, with lasting gains in measures such as forgiveness and sense of coherence [30]. Setting may matter even at the level of brain connections, though here the evidence is thin: a small 2026 PET study found no significant overall increase in a marker of synaptic density after psilocybin, but an exploratory comparison hinted at a more favorable signal when people were dosed in a comfortable room rather than inside the scanner [31]. No controlled trial has yet combined breathwork with psilocybin, and a US trial pairing psilocybin with an eight-week mindfulness course in healthy adults is still recruiting. Retreats use breathwork and meditation for preparation and integration because the mechanisms overlap; that is reasoned practice, not yet proven practice.
You don't owe anyone an extraordinary experience.
Chapter 7
How psilocybin compares with other psychedelics
I'm more interested in understanding the differences than declaring a winner.
| Compound | Main brain target | Acute duration | Best evidence | Status, October 2026 |
|---|---|---|---|---|
| Psilocybin | Serotonin 2A | 4–6 h | Depression, end-of-life distress, alcohol and tobacco | Two positive phase 3 trials; rolling FDA submission under way [14] |
| LSD (DT120, formerly MM120) | Serotonin 2A, plus dopamine | 8–12 h | Generalized anxiety: two positive phase 3 trials in 2026 | Application planned for the first half of 2027 [32] |
| MDMA | Serotonin release (not a classic psychedelic) | 3–6 h | PTSD: 71% vs 48% no longer met criteria [33] | FDA declined approval in August 2024; the developer (now Resilient Pharmaceuticals, formerly Lykos) reportedly resubmitted in August 2026; no decision as of October 2026 |
| Ketamine / esketamine | NMDA (glutamate), not serotonin | 1–2 h | Treatment-resistant depression; a single dose’s benefit fades within days to weeks | Esketamine spray approved 2019 |
| Ayahuasca / DMT | Serotonin 2A, with an MAO inhibitor | 4 h oral; under 20 min inhaled | Depression: one small randomized trial each for ayahuasca (29 people) and DMT (34 people) | Phase 2 |
| 5-MeO-DMT | Serotonin 1A and 2A | About 20 min | Treatment-resistant depression | Phase 3 under way for one compound (BPL-003) since mid-2026; a second (GH001) still planned for 2026 |
Chart 5 · Duration
A full psilocybin session fits inside an afternoon
Typical length of the acute experience, in hours; striped segments show the range
- 5-MeO-DMT about 20 min
- DMT, inhaled under 20 min
- Ketamine 1–2 h
- MDMA 3–6 h
- Ayahuasca, oral about 4 h
- Psilocybin 4–6 h
- LSD 8–12 h
Data: the comparison table above. Chart: Life Synergy.
Psilocybin leads the field partly for practical reasons: its session fits inside a day, unlike LSD’s; it avoids MDMA’s cardiovascular and overheating risks; its benefits last months rather than ketamine’s days to weeks; and it carries none of the dietary and drug restrictions of ayahuasca’s MAO inhibitor. The trade-off is intensity: a full dose is a demanding five or six hours.
Weighing the two plant traditions for a retreat? We compare them in Ayahuasca vs Psilocybin Retreats.
Chapter 8
Safety, screening and interactions with medications
I want the difficult questions asked before anyone packs a bag.
Psilocybin is physiologically gentle for a drug of its power: not toxic to organs at the doses studied, and not addictive. The risks are psychological and situational, which is why every trial above screened carefully. A 2024 meta-analysis of 114 psychedelic studies with usable side-effect data (3,504 participants) found no serious adverse events reported in healthy volunteers and about 4% among people with psychiatric conditions, including worsening depression, suicidal thoughts and, rarely, psychosis or seizures. No suicides or lasting psychotic disorders were reported after high doses in modern research, though the authors caution that side effects are often under-reported [34]. Outside clinics the picture is less tidy: in a survey of 1,993 people who had a difficult psilocybin experience, 84% still said they had benefited, but 7.6% sought treatment for lasting symptoms [35]. In Oregon’s regulated, non-medical program, an uncontrolled study of 346 clients found the share with moderate-to-severe depression fell by about 60% at three months (from 42% to 17%), and 4 clients (1.2%) had serious behavioral reactions [36].
- 0serious adverse events reported in healthy volunteers, across 114 studies and 3,504 participants [34]
- ~4%serious adverse events among people with psychiatric conditions [34]
- 7.6%sought treatment for lasting symptoms after a difficult experience outside clinics; 84% still said they benefited [35]
- 1.2%of 346 clients in Oregon’s regulated program had a serious behavioral reaction [36]
Who clinical guidelines exclude [37]
- Personal or close family history of schizophrenia or other psychotic disorders
- Personal or close family history of bipolar disorder
- Uncontrolled high blood pressure
- Significant heart disease
- Pregnancy
Medications matter, and the interactions are not all the same kind
Mostly blunt the experience
SSRIs and SNRIs
They mostly blunt the experience rather than making it dangerous. In a controlled study, two weeks of escitalopram reduced psilocybin’s anxious and unpleasant effects without serotonin toxicity [38]; in more than 600 reports from people taking antidepressants, about half of those on SSRIs described weaker effects, a dampening that may last up to three months after stopping [39].
The serious one
Lithium
In 62 online reports of lithium combined with a classic psychedelic, 47% involved seizures and 18% bad trips; lamotrigine reports showed neither [40].
Can intensify effects
MAO inhibitors and tricyclics
MAO inhibitors, including the harmala alkaloids in ayahuasca, and tricyclic antidepressants can intensify and prolong the effects unpredictably [37].
Excluded or paused
St John’s wort, 5-HTP, tramadol
They act on serotonin; clinical protocols exclude the first two [37], and tramadol, which also lowers the seizure threshold, is usually paused as a precaution.
With any prescription the right move is simple: tell the facilitators everything you take, and never stop or change a medication without the clinician who prescribed it.
How we screen every guest: Psilocybin Safety and Screening: What to Expect Before a Retreat, and the safety section of our retreat page.
Chapter 9
Two case studies from the literature
I can be moved by a person's story without making it a prediction for yours.
OCD · Yale · 2022
One dose, and a year later still free of OCD
A 33-year-old man had lived with obsessive-compulsive disorder since childhood and had not responded to several SSRIs or cognitive behavioral therapy. In a research unit he received a single dose of psilocybin. On a short-interval version of the standard OCD scale his score fell from 23 to 2 within 48 hours, and on the standard scale it reached 0 at twelve weeks. A year later he described himself as free of OCD apart from a brief, stress-related return of symptoms that settled within about two weeks [41].
Depression · France · 2025
Two ceremonies, and a lasting remission
French psychiatrists described a patient with recurrent depression that had responded only partially to escitalopram. In 2020 the patient, a Mexican student living in France, took part in two psilocybin ceremonies led by a shaman; there was partial improvement after the first, and about two weeks after the second the depression went into full remission, which the authors report has held without antidepressants since, while noting that other factors may have contributed [42].
One patient is not a trial, but the case mirrors the trial data.
Chapter 10
What this means if you are considering a retreat
I'd rather help you make a thoughtful decision than give you a reason to rush.
The science supports a few plain conclusions, and it is just as clear about what it does not support.
What the science supports
- A single, well-prepared psilocybin session can produce changes in mood, outlook and habits that last months, and the depth of the experience predicts how long they last.
- The brain is unusually moldable in the weeks afterwards, which makes integration, meditation and community the second half of the work, not an afterthought.
- Safety rests on screening, honesty about medications, and skilled, present guides.
What it does not support
- Guarantees. Trials are still small, and their participants were carefully selected.
- Claims about trauma or slowing aging. Those findings are early.
- Replacing medical care. Psilocybin is not an approved medicine and remains a controlled substance in most countries.
Life Synergy offers a guided wellness experience, not medical treatment. This page is educational, not medical advice; psilocybin is not an approved medicine and remains a controlled substance in most countries. Talk to your doctor or psychiatrist, and never adjust prescribed medication on your own.
Curious what a retreat looks like day to day? Read What Actually Happens During a Psilocybin Retreat?
The life you return to deserves as much attention as the ceremony.
From Juan
Take the questions home with you
If you take one thing from this page, I hope it's permission to be curious without having to be convinced. You can respect the science, feel drawn to the spiritual side, and still have practical questions. I'd be more concerned if you felt you had to put those questions aside to belong here.
For me, integration means giving an experience attention in the life you actually live. What still makes sense when you are home? What needs more reflection, or a conversation with someone qualified to help? Our program includes an individual integration call after your return. That is a place to continue the conversation, not a promise that everything will become clear or that change will follow.
Life Synergy is a guided wellness experience, not medical treatment, and we cannot guarantee benefits or outcomes. If you are considering joining us, you're welcome to talk with me about the program, the screening process, and your expectations. You don't need a polished intention or a beautiful explanation. A sincere question is a perfectly good place to begin.
Life Synergy Retreat · Playa del Carmen, Mexico
Let's talk, without the pressure
If you're curious about Life Synergy, I'd be happy to talk through the experience and your questions. You can also explore the dates and prices at your own pace.
A guided wellness experience, not medical treatment. Every guest is screened before acceptance.
Questions
Psilocybin research: frequently asked questions
Is psilocybin an approved medicine?
Not yet. As of October 2026, psilocybin is not an approved medicine in the United States and remains a controlled substance in most countries. Two phase 3 trials in treatment-resistant depression met their main goal in 2025 and 2026, and in April 2026 the FDA agreed to review the developer’s application on a rolling basis; the developer aims to complete its submission by the end of 2026. If the FDA accepts the application, a decision could follow in 2027. A Life Synergy retreat is a guided wellness experience, not medical treatment.
What does psilocybin do in the brain?
The body converts psilocybin into psilocin, which activates serotonin 2A receptors in the cortex. Brain scans show that the default mode network, linked to rumination and self-focus, quiets down, and that the brain’s usual network patterns loosen and then re-form. Animal studies show new connections between neurons within 24 hours, which is one reason the weeks after a session matter.
How long do the benefits of psilocybin last?
In the studies reviewed here, benefits often lasted months and sometimes years after one or two sessions. A year after the Johns Hopkins depression trial, 58% of participants remained in remission, and in a cancer study 60 to 80% still showed a clinically significant response about 4.5 years later. Results vary from person to person, and no study can promise any individual outcome.
Is psilocybin safe?
Psilocybin is not toxic to organs at the doses studied and is not addictive, but it is not risk-free. A 2024 review of 114 studies found no serious adverse events reported in healthy volunteers and about 4% among people with psychiatric conditions. Most risks are psychological and situational, which is why careful screening, preparation and skilled, present guides matter.
Can I take psilocybin if I am on antidepressants?
Tell the facilitators everything you take, and never stop or change a medication without the clinician who prescribed it. SSRIs and SNRIs mostly blunt the experience, and in survey reports that dampening sometimes lasted up to three months after stopping. Lithium is the serious one: nearly half of reports combining it with a classic psychedelic involved seizures. MAO inhibitors and tricyclics can intensify effects unpredictably.
Who should not take psilocybin?
Clinical safety guidelines exclude people with a personal or close family history of schizophrenia, other psychotic disorders or bipolar disorder, people with uncontrolled high blood pressure or significant heart disease, and anyone who is pregnant. Some medications, lithium above all, also rule people out. Life Synergy screens every guest, including medications and mental health history, before accepting them.
Does psilocybin work better with meditation or breathwork?
For meditation, two randomized studies suggest yes: experienced meditators on a retreat had deeper experiences with almost no anxiety, and support for a daily meditation practice boosted lasting benefits. No controlled trial has yet combined psilocybin with breathwork. Retreats pair them because the brain mechanisms overlap, which is reasoned practice, not yet proven practice.
Can psilocybin slow aging?
Nobody knows yet. The only study so far, published in 2025, found that psilocin extended the lifespan of human cells in the lab and that older mice given psilocybin once a month lived longer. These are cells and mice, not people, and the dosing bears no relation to how people use psilocybin. It is an interesting early frontier, not a reason to take it.
Is a psilocybin retreat a form of medical treatment?
No. A Life Synergy retreat is a guided wellness experience, not medical treatment, and this page is educational, not medical advice. Clinical trials use carefully selected participants, fixed protocols and licensed clinicians. If you live with a mental health condition, talk to your doctor or psychiatrist first, and never adjust prescribed medication on your own.
Sources
References
Numbers in the text link to this list. Links go to the journal (DOI) or to an open-access copy.
Show all 42 references
- Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268–283. doi.org/10.1007/s00213-006-0457-5
- Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology. 2008;22(6):621–632. doi.org/10.1177/0269881108094300
- Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS. 2012;109(6):2138–2143. doi.org/10.1073/pnas.1119598109
- Brewer JA, Worhunsky PD, Gray JR, et al. Meditation experience is associated with differences in default mode network activity and connectivity. PNAS. 2011;108(50):20254–20259. doi.org/10.1073/pnas.1112029108
- Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Reports. 2018;23(11):3170–3182. doi.org/10.1016/j.celrep.2018.05.022
- Shao LX, Liao C, Gregg I, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535–2544. doi.org/10.1016/j.neuron.2021.06.008
- Siegel JS, Subramanian S, Perry D, et al. Psilocybin desynchronizes the human brain. Nature. 2024;632:131–138. doi.org/10.1038/s41586-024-07624-5
- Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. doi.org/10.1001/jamapsychiatry.2020.3285
- Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. Journal of Psychopharmacology. 2022;36(2):151–158. Open-access PDF, Johns Hopkins
- Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine. 2021;384(15):1402–1411. doi.org/10.1056/NEJMoa2032994
- Erritzoe D, Barba T, Greenway KT, et al. Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. eClinicalMedicine. 2024;76:102799. doi.org/10.1016/j.eclinm.2024.102799
- Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 2022;387(18):1637–1648. doi.org/10.1056/NEJMoa2206443
- Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843–853. jamanetwork.com
- Compass Pathways. Phase 3 results for COMP360 psilocybin in treatment-resistant depression: COMP005 (June 2025) and COMP006 (February 2026), and FDA rolling review with a Commissioner’s National Priority Voucher (April 2026). COMP006 results · FDA rolling review
- Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084 (corrected February 2025). doi.org/10.1136/bmj-2023-078084
- Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. Journal of Psychopharmacology. 2016;30(12):1181–1197. doi.org/10.1177/0269881116675513
- Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology. 2020;34(2):155–166. doi.org/10.1177/0269881119897615
- Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953–962. jamanetwork.com
- Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse. 2017;43(1):55–60. PMC5641975
- Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A. Psilocybin or nicotine patch for smoking cessation: a pilot randomized clinical trial. JAMA Network Open. 2026;9(3):e260972. doi.org/10.1001/jamanetworkopen.2026.0972
- McGowan NM, et al. Open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder (n = 22). Journal of Psychopharmacology. Published online August 2025 (vol. 40, issue 1). doi.org/10.1177/02698811251362390 · Summary of results
- Armstrong S, et al. Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. Communications Medicine. 2026. nature.com
- Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology. 2018;8:974. doi.org/10.3389/fphar.2017.00974
- Kato K, Kleinhenz JM, Shin YJ, Coarfa C, Zarrabi AJ, Hecker L. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging. 2025;11:55. doi.org/10.1038/s41514-025-00244-x
- Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. International Review of Psychiatry. 2018;30(4):363–375. doi.org/10.1080/09540261.2018.1481827
- Havenith MN, et al. Decreased CO2 saturation during circular breathwork supports emergence of altered states of consciousness. Communications Psychology. 2025;3:59. doi.org/10.1038/s44271-025-00247-0
- Goyal M, Singh S, Sibinga EMS, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Internal Medicine. 2014;174(3):357–368. doi.org/10.1001/jamainternmed.2013.13018
- Fincham GW, Strauss C, Montero-Marin J, Cavanagh K. Effect of breathwork on stress and mental health: a meta-analysis of randomised-controlled trials. Scientific Reports. 2023;13:432. doi.org/10.1038/s41598-022-27247-y
- Smigielski L, Kometer M, Scheidegger M, Krähenmann R, Huber T, Vollenweider FX. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Scientific Reports. 2019;9:14914. doi.org/10.1038/s41598-019-50612-3
- Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology. 2018;32(1):49–69. doi.org/10.1177/0269881117731279
- Johansen A, Plavén-Sigray P, Madsen MK, et al. Psilocybin’s effect on human brain synaptic plasticity. Translational Psychiatry. 2026;16:544. nature.com
- Definium Therapeutics (formerly MindMed). Phase 3 Voyage (August 2026) and Panorama (September 2026) trials of DT120 (LSD; formerly MM120) in generalized anxiety disorder. Panorama results, SEC filing
- Mitchell JM, Ot’alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine. 2023;29:2473–2480. doi.org/10.1038/s41591-023-02565-4
- Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse events in studies of classic psychedelics: a systematic review and meta-analysis. JAMA Psychiatry. 2024;81(12):1225–1235. Johns Hopkins record
- Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. Journal of Psychopharmacology. 2016;30(12):1268–1278. doi.org/10.1177/0269881116662634
- Korthuis PT, et al. Safety and mental health outcomes of Oregon state-regulated psilocybin services. JAMA Network Open. 2026;9(8):e2630608. doi.org/10.1001/jamanetworkopen.2026.30608
- Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology. 2008;22(6):603–620. doi.org/10.1177/0269881108093587
- Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clinical Pharmacology & Therapeutics. 2022;111(4):886–895. doi.org/10.1002/cpt.2487
- Gukasyan N, Griffiths RR, Yaden DB, Antoine DG, Nayak SM. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. Journal of Psychopharmacology. 2023. doi.org/10.1177/02698811231179910
- Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry. 2021;54(5):240–245. doi.org/10.1055/a-1524-2794
- Kelmendi B, Kichuk SA, DePalmer G, et al. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: a case report. Heliyon. 2022;8:e12135. doi.org/10.1016/j.heliyon.2022.e12135
- Dumenil A, Cordova C, El-Hage W. Psilocybin in the setting of treatment-resistant unipolar depression: a case report (in French). L’Encéphale. 2025. doi.org/10.1016/j.encep.2025.02.007
